Influence of PAR-1 in patients with non-valvular atrial fibrillation: The antiplatelet effect of dabigatran

Dabigatran, a direct thrombin inhibitor, has been widely used in patients with non-valvular atrial fibrillation (NVAF) and is considered to have an antiplatelet effect. However, the mechanisms remain unclear. We evaluated protease-activated receptor-1 (PAR-1) expression and activation by thrombin on platelets from NVAF patients, before and after dabigatran treatment, in addition to the expression of platelet activation marker CD62P.

Source: Thrombosis Research - February 25, 2021 Category: Hematology Authors: Kiyotaka Oi, Mie Shimizu, Tatsunori Natori, Keisuke Tsuda, Makiko Yoshida, Asami Kamada, Yoko Ishigaku, Shinsuke Narumi, Kazumasa Oura, Tetsuya Maeda, Yasuo Terayama Source Type: research